Delineation of biomarkers and molecular pathways of residual effects of fluoxetine treatment in juvenile rhesus monkeys by proteomic profiling  

作　　者：Yu Yan Dong Ik Park Anja Horn Mari Golub Christoph W.Turck 

机构地区：[1]Proteomics and Biomarkers,Max Planck Institute of Psychiatry,Munich 80804,Germany [2]Ludwig-Maximilians-Universität,Chair of Vegetative Anatomy,Institute of Anatomy,Faculty of Medicine,Munich 80336,Germany [3]Department of Environmental Toxicology,University of California,Davis,CA 95616,USA

出　　处：《Zoological Research》2023年第1期30-42,共13页动物学研究（英文）

基　　金：supported by the Max Planck Society to C.W.T.and National Institutes of Health USDHHS(R01-HD065826to M.G.,OD011107 to Harris Lewin)。

摘　　要：Fluoxetine(Prozac^(TM))is the only antidepressant approved by the US Food and Drug Administration(FDA)for the treatment of major depressive disorder(MDD)in children.Despite its considerable efficacy as a selective serotonin reuptake inhibitor,the possible long-term effects of fluoxetine on brain development in children are poorly understood.In the current study,we aimed to delineate molecular mechanisms and protein biomarkers in the brains of juvenile rhesus macaques(Macaca mulatta)one year after the discontinuation of fluoxetine treatment using proteomic and phosphoproteomic profiling.We identified several differences in protein expression and phosphorylation in the dorsolateral prefrontal cortex(DLPFC)and cingulate cortex(CC)that correlated with impulsivity in animals,suggesting that the GABAergic synapse pathway may be affected by fluoxetine treatment.Biomarkers in combination with the identified pathways contribute to a better understanding of the mechanisms underlying the chronic effects of fluoxetine after discontinuation in children.

关 键 词：Major depressive disorder FLUOXETINE Rhesus monkeys PROTEOMICS GABAergic synapse 

分 类 号：Q95[生物学—动物学]